6550--HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
262-NETWORK CONTRACT OFFICE 22 (36C262)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C26227Q0111
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
6550
Additional Details
Documents4
The Department of Veterans Affairs, through its Network Contract Office 22 (NCO 22), has issued a Combined Synopsis/Solicitation for the procurement of Hemochron Signature Elite reagents and supplies. This opportunity, identified by procurement number 36C26227Q0111, is intended to support the ongoing diagnostic needs at the VA facility located in Tucson, Arizona.
The primary purpose of this procurement is to secure a reliable supply of specialized reagents and consumables compatible with the Hemochron Signature Elite system, which is used for in-vitro diagnostic testing. The scope encompasses the provision of these products to ensure uninterrupted clinical operations and accurate diagnostic results for veteran patients. The expected outcome is the maintenance of high-quality laboratory services, supporting the VA’s commitment to patient care and safety.
Key requirements include the supply of reagents and consumables that meet the specifications for in-vitro diagnostic substance manufacturing, as classified under NAICS code 325413. The relevant Product Service Code is 6550, indicating a focus on medical and laboratory supplies. Contractors must be able to deliver these products to the VA facility in Tucson, Arizona, and ensure compliance with applicable federal standards and regulations.
The contracting entity is the Network Contract Office 22 (NCO 22), a federal office within the Department of Veterans Affairs. The primary point of contact for this solicitation is Rebecca Gaba, who can be reached via email at [email protected] for any questions or clarifications regarding the opportunity.
This procurement is posted as a Combined Synopsis/Solicitation, streamlining the process for interested vendors. The notice remains active, with a response deadline set for November 27, 2026. Contractors are encouraged to review the attached documents for detailed specifications and submission requirements. No set-aside requirements or special considerations are specified in the provided information.
For further details and access to attachments, contractors should refer to the official notice on SAM.gov at https://sam.gov/opp/d53bea33b0dc429080fad1c6cbe09707/view.
This opportunity is well-suited for suppliers specializing in in-vitro diagnostic substances, particularly those with experience supporting federal healthcare facilities. The contract will require consistent quality, timely delivery, and adherence to VA standards throughout its lifecycle.